Nuvectis Pharma Insiders Enjoying US$141k Appreciation On US$1.17m Investment

Last week, Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares increased by 13% last week, resulting in a US$130m increase in the company's market worth, implying a 12% gain on their initial purchase. As a result, the stock they originally bought for US$1.17m is now worth US$1.31m.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

The Last 12 Months Of Insider Transactions At Nuvectis Pharma

In the last twelve months, the biggest single purchase by an insider was when insider Charles Mosseri-Marlio bought US$916k worth of shares at a price of US$18.32 per share. Even though the purchase was made at a significantly lower price than the recent price (US$20.91), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

While Nuvectis Pharma insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

View our latest analysis for Nuvectis Pharma

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of Nuvectis Pharma

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Nuvectis Pharma insiders own 32% of the company, worth about US$202m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Does This Data Suggest About Nuvectis Pharma Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. With high insider ownership and encouraging transactions, it seems like Nuvectis Pharma insiders think the business has merit. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Nuvectis Pharma. Be aware that Nuvectis Pharma is showing 4 warning signs in our investment analysis, and 2 of those are a bit unpleasant...

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.